Cargando…

P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2

Detalles Bibliográficos
Autores principales:	Walewski, Jan, Min Kim, Tae, Cho, Seok-Goo, Jarque, Isidro, Iskierka-Jażdżewska, Elżbieta, Poon, Michelle, Miles Prince, H., Yong Oh, Sung, Lim, Francesca, Segura, Cecilia Carmen Carpio, Tan, Tran-Der, Ayyappan, Sabarish, Gutiérrez, Antonio, LI, Jingjin, Ufkin, Melanie, Zhu, Min, Chaudhry, Aafia, Mohamed, Hesham, Ambati, Srikanth, Kim, Won-Seog
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431082/ http://dx.doi.org/10.1097/01.HS9.0000971356.50570.ac

Ejemplares similares

P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
por: Taszner, Michał, et al.
Publicado: (2023)

PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)
por: Novelli, Silvana, et al.
Publicado: (2023)

PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY
por: Cho, Seok-Goo, et al.
Publicado: (2023)

PB2267: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-1)
por: Luminari, Stefano, et al.
Publicado: (2023)

Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
por: Weinstock, Matt, et al.
Publicado: (2022)

PB2343: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS STANDARD OF CARE THERAPY IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (OLYMPIA-4)
por: Hawkes, Eliza A., et al.
Publicado: (2023)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
por: Vitolo, Umberto, et al.
Publicado: (2023)

PB2366: TRIAL IN PROGRESS: PHASE 1 TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF ODRONEXTAMAB IN COMBINATION WITH CEMIPLIMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Segura, Cecilia Carmen Carpio, et al.
Publicado: (2023)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
por: Tessoulin, Benoit, et al.
Publicado: (2023)

PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Mutsaers, Pim G. N. J., et al.
Publicado: (2023)

Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies
por: Zhu, Min, et al.
Publicado: (2022)

Innovations in Section 1115 Demonstrations
por: Jordan, Joyce, et al.
Publicado: (2000)

State Health Reform and the Role of 1115 Waivers
por: Riley, Trish
Publicado: (1995)

Why elm?
por: Griffith, Matthew
Publicado: (2017)

Elm in Action
por: Feldman, Richard
Publicado: (2020)

Programming Elm
por: Fairbank, Jeremy
Publicado: (2019)

Association of Indiana’s Section 1115 Waiver With Medicaid Enrollment
por: Stimpson, Jim P., et al.
Publicado: (2019)

Complexities underlying the breeding and deployment of Dutch elm disease resistant elms
por: Martín, Juan A., et al.
Publicado: (2021)

Proceedings of elm 2018
por: Cao, Jiuwen, et al.
Publicado: (2019)

Vaccination of Elms against Dutch Elm Disease—Are the Associated Epiphytes and Endophytes Affected?
por: Witzell, Johanna, et al.
Publicado: (2023)

Elm Web development: an introductory guide to building functional web apps using Elm
por: Imsirovic, Ajdin
Publicado: (2018)

Bark and wood tissues of American elm exhibit distinct responses to Dutch elm disease
por: Sherif, S. M., et al.
Publicado: (2017)

Determing the Hubble constant from the gravitational lens PG 1115+080
por: Keeton, C R, et al.
Publicado: (1996)

Budget Impact of Medicaid Section 1115 Demonstrations for Early HIV Treatment
por: Schackman, Bruce R., et al.
Publicado: (2005)

1115 Impact of a Publicly Funded Rotavirus Vaccine in Quebec, Canada
por: Comeau, Jeannette, et al.
Publicado: (2014)

Association of Arkansas’s section 1115 Medicaid waiver with health insurance coverage
por: Stimpson, Jim P., et al.
Publicado: (2020)

1115. A Longitudinal Medical Education Program for Infectious Diseases Fellows
por: Steinbrink, Julie M, et al.
Publicado: (2020)

Elm1 sparks the SPOC
por: Leslie, Mitch
Publicado: (2010)

On Bougies of Slippery Elm Bark
por: Herrick, Wm. B.
Publicado: (1845)

Novel and emerging therapies for B cell lymphoma
por: Ayyappan, Sabarish, et al.
Publicado: (2019)

Correction to: Novel and emerging therapies for B cell lymphoma
por: Ayyappan, Sabarish, et al.
Publicado: (2021)

Resistance to Dutch Elm Disease Reduces Presence of Xylem Endophytic Fungi in Elms (Ulmus spp.)
por: Martín, Juan A., et al.
Publicado: (2013)

Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease
por: Yao, Fangfang, et al.
Publicado: (2019)

1115. Evaluation of Gepotidacin (GSK2140944) Pharmacokinetics and Food Effect in Japanese Subjects
por: Hossain, Mohammad, et al.
Publicado: (2021)

Cold Treatment Induces Transient Mitochondrial Fragmentation in Arabidopsis thaliana in a Way that Requires DRP3A but not ELM1 or an ELM1-Like Homologue, ELM2
por: Arimura, Shin-ichi, et al.
Publicado: (2017)

ELM—the database of eukaryotic linear motifs
por: Dinkel, Holger, et al.
Publicado: (2012)

Elm Tents for the Dilatations of the Cervix Uteri
Publicado: (1856)

Treatment of Tape-Worm with Elm Bark
por: Dowler, J. R.
Publicado: (1865)

Atypical Chronic Lymphocytic Leukemia—The Current Status
por: Robak, Tadeusz, et al.
Publicado: (2023)

Simultaneous induction of jasmonic acid and disease-responsive genes signifies tolerance of American elm to Dutch elm disease
por: Sherif , S. M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3qk5lobcoit5qjmkc3vvreb6g5